[The effect of the parameters of the therapeutic protocol on the efficacy of the adjuvant chemotherapy of breast cancer].
A 5-year relapse-free survival was analyzed in two groups of patients with stage II breast cancer, having received adjuvant chemotherapy (AChTh). The efficiency of adjuvant monochemotherapy with thiophosphamide is inferior to results of employment with the same purpose of six cycles of CMP. The results of AChTh with thiophosphamide appeared to be related to the total dose of the drug. With its course dose of up to 200 mg the value for a 5-yr relapse-free survival is half as much as the efficiency of treatment of those patients having received more than 210 mg of the drug. Similarly, deviations from the requirement of the standard CMP protocol (100-40-600, 6 cycles with a 29-day interval) toward reduction of single doses of cytostatics and diminution of the number of chemotherapy cycles are accompanied by a significant worsening of long-term results of supplementary treatment. Efficiency of AChTh in circumscribed affection of regional lymphatic nodes is much higher than in the presence of four and more lymph-nodal metastases.
Nekhme
A
A
D018906:Antineoplastic Agents, Alkylating / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery; D017024:Chemotherapy, Adjuvant; D002985:Clinical Protocols; D003520:Cyclophosphamide / Q000008:administration & dosage; D018572:Disease-Free Survival; D004305:Dose-Response Relationship, Drug; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage; D006801:Humans; D008207:Lymphatic Metastasis; D008727:Methotrexate / Q000008:administration & dosage; D009367:Neoplasm Staging; D011182:Postoperative Care; D012189:Retrospective Studies; D013852:Thiotepa / Q000008:administration & dosage
D018906:Antineoplastic Agents, Alkylating; D003520:Cyclophosphamide; D013852:Thiotepa; D005472:Fluorouracil; D008727:Methotrexate